Big Pharma Has Spent $8 Billion on Targeted Radiation. Alpha Tau Is Building for the Tumors They Can’t Reach
TL;DR: Alpha Tau Medical Ltd. (NASDAQ: DRTS) is developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. Since late 2023, pharmaceutical giants have spent nearly $8 billion acquiring systemic radiopharmaceutical platforms that deliver radioactive payloads through the bloodstream. These work well for metastatic cancers but have limitations





